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Background: Surrogate outcomes are a significant challenge in drug evaluation for health technology assessment
(HTA) agencies. The research objectives were to: identify factors associated with surrogate use and acceptability in
Canada’s Common Drug Review (CDR) recommendations, and compare the CDR with other HTA or regulatory
agencies regarding surrogate concerns.
Methods: Final recommendations were identified from CDR inception (September 2003) to December 31, 2010.
Recommendations were classified by type of outcome (surrogate, final, other) and acceptability of surrogates
(determined by the presence/absence of statements of concern regarding surrogates). Descriptive and statistical
analyses examined factors related to surrogate use and acceptability. For thirteen surrogate-based submissions,
recommendations from international HTA and regulatory agencies were reviewed for statements about surrogate
acceptability.
Results: Of 156 final recommendations, 68 (44%) involved surrogates. The overall ‘do not list’ (DNL) rate was 48%;
the DNL rate for surrogates was 41% (p = 0.175). The DNL rate was 64% for non-accepted surrogates (n = 28) versus
25% for accepted surrogates (odds ratio 5.4, p = 0.002). Clinical uncertainty, use of economic evidence over price
alone, and a premium price were significantly associated with non-accepted surrogates. Surrogates were used most
commonly for HIV, diabetes, rare diseases, cardiovascular disease and cancer. For the subset of drugs studied, other
HTA agencies did not express concerns for most recommendations, while regulatory agencies frequently stated
surrogate acceptance.
Conclusions: The majority of surrogates were accepted at the CDR. Non-accepted surrogates were significantly
associated with clinical uncertainty and a DNL recommendation. There was inconsistency of surrogate acceptability
across several international agencies. Stakeholders should consider collaboratively establishing guidelines on the
use, validation, and acceptability of surrogates.
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In 2003, the Common Drug Review (CDR) was created to
provide a single national process to review the comparative
clinical evidence and cost-effectiveness of new drugs, and
to make formulary listing recommendations to Canadian
publicly funded federal, provincial and territorial drug
benefit plans (excluding Quebec) [1]. A centralized review
process was intended to mitigate inconsistencies which
existed across jurisdictions, both in drug review expertise
and drug access. The CDR process and the requirements* Correspondence: angela@axiaresearch.com
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at www.cadth.ca [2,3].
A recent Canadian publication examined trends and
predictors in CDR recommendations. Under logistic re-
gression, four factors were found to be significantly asso-
ciated with a ‘do not list’ (DNL) recommendation: a
statement of clinical uncertainty, a request for reconsider-
ation (a form of appeal), the use of price as the only eco-
nomic evidence, and price greater than comparators [4]. A
comparison of recommendations from Canada, Australia
and the UK also found that clinical uncertainty was a key
issue, with uncertainty typically arising from inadequate
study design, inappropriate comparators or unvalidatedLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Rocchi et al. Cost Effectiveness and Resource Allocation 2013, 11:31 Page 2 of 10
http://www.resource-allocation.com/content/11/1/31surrogate endpoints [5]. That study concluded that all
three agencies “face common issues with respect to the
quality and strength of experimental evidence in support
of a clinically meaningful effect”. Further, chairs of the
CDR’s expert advisory panel have noted that clinical un-
certainty, and specifically surrogate outcomes, remain one
of their greatest challenges [6].
Surrogate outcomes are defined as a laboratory meas-
urement or a physical sign used as a substitute for a
clinically meaningful endpoint that measures directly
how a patient feels, functions or survives, and that is ex-
pected to predict the effect of the therapy [7]. Surrogates
are often biomarkers such as hemoglobin A1C [HbA1c],
blood pressure, lipid levels, etc. Surrogate outcomes are
used in clinical trials for reasons of efficiency and practi-
cality; they can be measured with fewer patients, less in-
vasiveness and a shorter observation period [8]. Where
surrogate outcomes have validated links with final end-
points, their use can greatly facilitate clinical research.
However, in the absence of validated links, there can be
uncertainty about patient benefit; and even where the epi-
demiologic basis is sound, long-term safety and other un-
anticipated issues may predominate [9]. For example, while
blood pressure is conclusively linked to cardiovascular
morbidity and mortality, antihypertensive drugs do not ne-
cessarily reduce morbidity or mortality as expected [10].
In contrast, a final outcome produces an end unit of
health effect: survival, cure, or prevention of such an event
(such as pregnancy or infection). For therapeutic areas
where mortality or cure is not a relevant measure, clinical
endpoints and scales measure how a patient feels or func-
tions, but not survives (such as disability scores, depression
scales, psoriasis severity, arthritic joint counts, incontin-
ence episodes, etc.).
Surrogate outcomes have become fundamental to drug
development, but their use in regulatory decision-making
is regularly questioned when large observational studies
reveal unpredicted mortality from effective drugs. Regula-
tory agencies such as the United States’ Food and Drug
Administration (FDA) have supported the formal inclu-
sion of surrogate outcomes in the regulatory process. The
FDA’s Critical Path Initiative identified surrogate outcomes
as an important opportunity to evaluate and predict the
safety, effectiveness, and manufacturability of medical pro-
ducts [11]. At the same time, the FDA has also instituted a
requirement for evaluating the cardiovascular risk of new
diabetes drugs, based on unexpected cardiovascular events
among diabetic patients treated with rosiglitazone, whose
metabolic effects were expected to reduce, rather than in-
crease, such events [12,13].
Beyond regulatory approval, health technology assess-
ment (HTA) agencies also review evidence based on sur-
rogate outcomes. In contrast to the US regulator, HTA
agencies are often cautious about the use of surrogateoutcomes, and in many cases have developed methodo-
logical guidelines for the use and validation of surrogate
outcomes [14]. Furthermore, for HTA agencies that re-
view cost-effectiveness data, surrogates are often used as
the basis for cost-effectiveness research [15]. HTA agen-
cies are dependent on the drug development evidence
base as influenced by the regulator. These two different
audiences may have different informational needs [16].
Regulators may be more focused on safety and shorter-
term efficacy and registration trials are specifically de-
signed to answer these questions, usually with guidance
from regulatory agencies. HTA agencies may focus on a
longer-term perspective, and the occurrence or preven-
tion of downstream ‘hard’ events. These may not be ad-
dressed within the registration trial data package or the
focus on short-term outcomes. This may result in different
perspectives on the acceptability of surrogates, which could
be revealed by a comparison of the two types of agencies.
While the CDR does not have a formal position or
guideline on the use of surrogate outcomes, some rec-
ommendations have included statements that show con-
cern for the use of surrogates and their relationship to
patient benefit. These statements of concern have varied
both within and between drugs and therapeutic areas. It
is important to investigate whether surrogate concerns
may lead to higher rates of clinical uncertainty, and thus
impact the evaluation drugs in therapeutic areas where
surrogate use is common.
The objectives of this research were to identify factors
associated with surrogate use and acceptability at the
CDR, and to compare the CDR with other HTA or regu-
latory agencies regarding surrogate concerns.
Methods
Databases
The CDR analysis constituted all published recommen-
dations from inception (September 2003) to December
31, 2010. ‘Final Recommendations and Reasons for Rec-
ommendation’ were retrieved from the CADTH website
(www.CADTH.ca). The same drug could have had mul-
tiple reviews and recommendations. For drugs that had
multiple submissions for the same indication, qualitative
statements about surrogates were abstracted from all
recommendations, although only the most recent rec-
ommendation was used to determine the final listing
recommendation. For example, insulin detemir was ini-
tially reviewed by CEDAC in June 2005 for the treat-
ment of Type 1 and 2 diabetes mellitus. A resubmission
for the same indication (based on new information) was
reviewed in July 2006. The final listing recommendation
was determined from the 2006 resubmission, but quali-
tative statements about surrogates could be drawn from
either submission. In contrast, subsequent submissions
for previously-reviewed drugs that were based on new
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ommendations. For example, insulin detemir was resub-
mitted in 2009 for a new indication (Type 1 diabetes in
pediatric patients). This second indication was included
in the dataset as a separate, unique submission.
The CDR has multiple types of recommendations. ‘Do
not list’ was a negative recommendation; all others were
considered a positive recommendation (‘list’, ‘list in a
similar manner to other drugs in the same class’ and ‘list
with conditions/criteria’).
For the international comparison of the CDR to other
agencies, rather than investigating all 68 drug submissions
which involved a surrogate, a convenience sample was se-
lected of submissions from therapeutic areas where sur-
rogate use was common, surrogate acceptability was
questioned, and the same surrogate was used across mul-
tiple submissions (at least three drugs in each therapeutic
area in order to have a reasonable sample). All submis-
sions from three therapeutic areas were examined: type 2
diabetes oral drugs (3 drugs), hepatitis (5 drugs) and pul-
monary arterial hypertension (5 drugs). Therapeutic areas
where surrogate use was unquestioned were excluded
from the international comparison. For example, HIV drugs
and insulin therapies were excluded because the CDR
never stated any concerns about the surrogate outcomes
as used in these areas (viral load and HbA1c respectively).
Others (rare diseases, cancer) were impractical to investi-
gate as a group because there was too much disease het-
erogeneity within the category and limited use of the same
surrogate across submissions.
The HTA agencies selected for comparison included the
English-language central review agencies which post de-
tailed recommendations and to which the CDR is regularly
compared: Australia’s Pharmaceutical Benefits Advisory
Committee (PBAC), Scotland’s Scottish Medicines Consor-
tium (SMC) and England’s National Institute for Health
and Clinical Excellence (NICE) [5,16,17]. The regulatory
agencies were: Health Canada (to compare with the CDR),
European Medicines Agency (EMA, to compare with the
SMC and NICE) and the Food and Drug Administration
(FDA, as the largest and most influential single regulatory
agency). For these agencies, websites were searched to de-
termine the initial and all subsequent reports and recom-
mendations on the indications under consideration by
the CDR: the ‘Summary Basis for Decision’ from Health
Canada, the reviewers reports (‘Medical’ ‘Clinical’ or ‘Sum-
mary’) from the Centre for Drug Evaluation and Research
for the FDA, and the ‘Assessment Report’ or ‘CHMP As-
sessment Report’ for the EMA.
Data abstraction
A database of CDR submissions was developed initially
using the information available in the public recommen-
dations. Data were abstracted for variables under fourdistinct categories of inquiry: submission specifics, drug
characteristics, clinical evidence, and economic evidence.
All variable responses had formal definitions, developed
by the abstractors. Any database disagreements were re-
solved by discussion between the two abstractors. Full de-
tails of the methodology to establish the CDR database are
found in an earlier publication [4].
For a number of variables, particularly for the clinical
and economic evidence, there was insufficient and/or in-
consistent information available in the public documents.
As a result, some response definitions reflected whether
information was stated or identified, with the alternate re-
sponse option being ‘not stated’ or ‘not identified’. For ex-
ample, clinical uncertainty required an explicit statement
that the clinical evidence was ‘unknown’ ‘uncertain’ ‘un-
proven’ ‘insufficient’ or ‘not sufficient’. If a definitive state-
ment regarding clinical uncertainty was not present, then
the response assigned was ‘not identified’. Similarly,
outcomes were defined as ‘not acceptable’ only if there
was an explicit statement of such. There were no explicit
statements that the chosen outcome was acceptable.
Therefore, for all other outcomes, their acceptability was
‘not identified’.
For the current analysis, the original CDR database was
extended by adding the type of outcome: surrogate, final
or ‘other’ (clinical endpoints and scales). A surrogate out-
come was defined as a biomarker intended to substitute
for a clinical endpoint, such as: HbA1C, viral load, 6 mi-
nute walk distance (6MWD), blood pressure, lipid levels,
forced expiratory volume, intraocular pressure, and bio-
chemistry. Surrogate outcomes were further classified into
‘accepted’ or ‘not accepted’ using the methodology above –
that there had to be an explicit statement of concern about
the surrogate, or a stated preference for alternative out-
comes. All other responses and non-responses were clas-
sified by default as ‘accepted’. Note, for an ‘accepted’
surrogate, there could be explicit negative statements
about other aspects of the clinical use of the outcome
(such as study design issues), but not about the outcome
itself. This binary system of classification was used for the
analysis that was limited to CDR recommendations.
Final outcomes were limited to: death, cure or preven-
tion of event (e.g. pregnancy). All other outcomes were
defined as ‘other’ and constituted clinical endpoints or
scales. For some therapeutic areas (such as mental health,
neurology, or analgesia), tools such as endpoints or scales
were the appropriate measures of disease status. These
tools ideally would be objective, reproducible and with
minimal measurement bias. Examples include: ACR 20 for
assessment of rheumatology diseases, EDSS for assess-
ment of multiple sclerosis, or HAM-D for major depres-
sive disorder.
All drugs in this analysis were approved in Canada
under routine drug development pathways. Only a small
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trials. It was reasonable to assume that all clinical trial
outcomes were reviewed by appropriate regulatory agen-
cies, and that clinical experts agreed the trial outcomes
represented appropriate, valid measurements of disease
status and drug efficacy for phase IIIA drug development
trials.
For the international comparison, two researchers
(AR, PD) searched each agency website to obtain rele-
vant documents and identify sections within each docu-
ment that concerned surrogates, while both researchers
abstracted data and resolved all disagreements and dis-
crepancies. For each drug, statements regarding surro-
gates were examined and classified under ten levels of
acceptability (Table 1). CDR recommendations were re-
reviewed and re-classified using this more extensive
system for the international comparison (replacing the
binary classification used in the CDR-only analysis). Under
either system, however, it remained true that there had to
be explicit statements to support lack of acceptability.
Supporting statements to justify the classification were re-
corded in the database. Other abstracted data included:
date of review, funding recommendation, reimbursement
criteria, and preferred outcomes (if stated). If available,
national guidelines were obtained and compared to the
funding recommendation as well as the qualitative surro-
gate comments.
Some reviews included both supportive and critical
statements about a surrogate. For a review that resulted
in a negative recommendation, it was assumed that the
critical statements were more representative of the
agency’s views on the surrogate. In this case, the surro-
gate was assigned to one of the non-accepted categories.
For a review that resulted in a positive recommendation,
it was assumed that the supportive statements were
more representative of the agency’s views on the surro-
gate. In this case, the surrogate was assigned one of the
‘accepted’ levels, but a statement of concern was noted.Table 1 Classification system for surrogate acceptability
Explicit yes = yes (e) Statement that the su
Implicit yes* ‘Used before’ = yes (ref) Statement that the su
‘Guidelines’ = yes (guid) Statement that the su
‘Evidence 1’ = yes (e1) Statement that there i
‘Evidence 2’ = yes (e2) Statement that there i
No statement = (N/S) No qualitative stateme
Not applicable = (N/A) No review was condu
Implicit no ‘Reference’ = no (ref) Statement of referenc
‘Evidence 2’ = no (e2) Statement that there i
Explicit no ‘Evidence 1’ = no (e1) Statement that there i
*Could additionally record a statement of concern.Statistical analysis
Every unique recommendation was considered a separ-
ate observation. Once all recommendations were catego-
rized, descriptive statistics were performed, to identify
characteristics associated with surrogates overall and
with accepted versus non-accepted surrogates. The focus
was on the recommendation status (DNL versus list)
and the factors that were previously proven to be associ-
ated with a DNL.
Differences across HTA agencies were descriptively pre-
sented as Yes/No indications of statements concerning sur-
rogate acceptability for the drugs included in the analysis.Factors associated with surrogate use
Drug recommendations and all factors significantly asso-
ciated with a DNL in the previous publication by Rocchi
et al. [4] were individually tested for independence.
These variables were tested against the three type of out-
comes (final, others, surrogates) using chi-square tests
with degrees of freedom of (rows-1)×(columns-1) and a
level of significance (α) of 0.05. When a variable was
rejected for independence (p < 0.05), a statistically sig-
nificant association was determined to be present be-
tween the tested variables.Factors associated with surrogate acceptability
In the binary univariate logistic analysis, a regression
with surrogate acceptability as the dependent variable
(not accepted = 1, and accepted = 0) was run against var-
iables that were associated with DNL in the study con-
ducted by Rocchi et al. [4] and against other covariates
such as first in class, first in disease, life threatening dis-
ease and priority review requested. An OR > 1 indicated
that the presence of a factor (e.g. clinical uncertainty,
higher price, etc.) was statistically associated with non-
accepted rather than accepted surrogates [18]. Associa-
tions were significant at p < 0.05.rrogate was accepted, valid, established or clinically relevant
rrogate has been used for other, earlier drugs in this indication
rrogate is identified in guidelines as appropriate
s some evidence linking the surrogate to the final outcome
s some evidence linking the drug to the final outcome
nt whether the surrogate was acceptable or not
cted or available
e to other (preferred) outcomes but no direct comment on the surrogate
s no evidence linking the drug to final outcomes
s no evidence linking the surrogate outcome to final outcomes
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Dataset disposition
From inception to December 31, 2010, there were 156
final unique recommendations. Of these, there were 68
surrogate outcomes (44%), 26 final outcomes (17%), and
the remaining 62 (44%) were ‘other’ (clinical endpoints
and scales). Of the 68 surrogate outcomes, 28 were ex-
plicitly defined as ‘not accepted’ (41% of the surrogate
outcomes). The remaining 40 drugs (59%) did not have
any explicit negative statements and were classified by
default as ‘accepted’.CDR analysis
Reimbursement recommendation
Of the 156 recommendations under review, there were
77 DNL recommendations, for an overall 48% DNL rate.
Table 2 depicts the results of the CDR analysis.
There was a gradient of approval based on type of out-
come: final outcomes were associated with the highest
DNL rate at 58%, followed by ‘other’ at 52%. Surrogate
outcomes had the lowest rate of rejection at 41%. These
differences were not statistically significant.
The DNL rate was significantly different based on surro-
gate acceptability. For non-accepted surrogates, the DNL
rate was higher at 64%; for accepted surrogates, the DNL
rate was lower at 25% (odds ratio [OR] of a DNL for a
non-accepted versus an accepted surrogate: 5.4, p = 0.002,
Tables 2 and 3).Factors associated with surrogate acceptability
The distribution of clinical uncertainty mirrored the reim-
bursement recommendation closely, as was demonstrated
in the original CDR analysis [4]. Clinical uncertainty was
most likely to be present for submissions using ‘other’ out-
comes (58%; p = 0.999), followed by submissions using
final outcomes (50%; p = 0.062). Clinical uncertainty was
least likely to be present for submissions using surrogate
outcomes (38%; p = 0.045).
If the surrogate was assigned ‘acceptable’, then clinical
uncertainty was present for only 20% of submissions. In
contrast, 64% of submissions with non-accepted surro-
gates had clinical uncertainty (OR of clinical uncertaintyTable 2 Percentage of drug recommendations based on outco
Factor Final outcome¥ (n = 26)
DNL recommendation 15/26 (58%)
Statement of clinical uncertainty 13/26 (50%)
Price only economic factor 12/26 (46%)
Economic considered 11/26 (42%)
Price greater than comparators 19/26 (73%)
¥Final outcome = end unit of health effect.
*Other = clinical endpoints and clinical scales.
§Surrogate outcome = biomarker intended to substitute for a clinical endpoint.for a non-accepted versus an accepted surrogate: 7.2, p <
0.001, Tables 2 and 3).
Consideration of economic evidence was categorized as
‘clinical undetermined’ (no consideration of economic evi-
dence including price), ‘economic considered’ (where there
was mention of an economic model or cost-effectiveness)
and ‘price only’. The distribution between ‘economic con-
sidered’, ‘price only’ and ‘clinical undetermined’ was quite
consistent across the three types of outcomes. However,
within the category of surrogates, differences emerged. For
the majority (70%) of accepted surrogates, the discussion
involved only price. This suggested a simplified decision-
making process for these cases: drugs were deemed equiva-
lently efficacious and similarly priced. The odds ratio for
using price only for non-accepted versus accepted surro-
gates was 0.1 (p < 0.001, Table 3), confirming that recom-
mendations with price as the only economic evidence are
less likely to have concerns regarding the surrogate. For
the majority (61%) of non-accepted surrogates, the discus-
sion considered economic evidence in the form of a model
or cost-effectiveness results – suggesting a more complex
consideration of a product’s value (OR for economic evi-
dence with a non-accepted versus accepted surrogates: 4.1;
p = 0.007, Table 3).
Price was categorized into a binary variable: (1) greater
than all CEDAC-identified comparators or at the same
price as the most expensive comparator cited by CEDAC,
and (2) all other responses. For accepted surrogates, price
was greater than comparators for only 33% of sub-
missions, but price was greater almost twice as often for
non-accepted surrogates (57%, OR for price greater than
comparator for non-accepted versus accepted surrogates:
2.8; p = 0.046, Table 3).
The fourth factor which was significantly associated
with a DNL was a request for reconsideration, a manu-
facturer choice that is unrelated to the clinical or eco-
nomic characteristics of a drug and consequently was
not reported in this analysis.
Therapeutic area
The use of different types of outcomes was not ran-
domly distributed across therapeutic area (Figure 1),
nor was surrogate acceptability (Figure 2). For example,me
Other outcome* (n = 62) Surrogate outcome§ (n = 68)
32/62 (52%) 28/68 (41%)
36/62 (58%) 26/68 (38%)
30/62 (48%) 34/68 (50%)
29/62 (47%) 28/68 (41%)
30/62 (48%) 29/68 (43%)
Table 3 Analysis of the drug recommendations with surrogate outcomes








Factors Associated with a DNL
DNL recommendation 10/40 (25%) 18/28 (64%) 5.4 (1.9-15.5) [p = 0.002]
Clinical uncertainty 8/40 (20%) 18/28 (64%) 7.2 (2.4-21.5) [p < 0.001]
Price Only 28/40 (70%) 6/28 (21%) 0.1 (0.0-0.4) [p < 0.001]
Economic considered 11/40 (28%) 17/28 (61%) 4.1 (1.4-11.4) [p = 0.007]
Price greater than comparators 13/40 (33%) 16/28 (57%) 2.8 (1.0-7.5) [p = 0.046]
Other Factors
First in class 6/40 (15%) 14/28 (50%) 5.7 (1.8-17.7) [p = 0.003]
First in disease 2/40 (5%) 5/28 (18%) 4.1 (0.7-23.1) [p = 0.106]
Life threatening 3/40 (8%) 9/28 (32%) 5.8 (1.4-24.1) [p = 0.015]
Priority review requested 7/40 (18%) 9/28 (32%) 2.2 (0.7-7.0) [p = 0.166]
∞; Odds Ratio > 1 is associated with higher odds of the surrogate not being accepted given the presence of a factor.
*Bold p values indicate statistical significance under univariate analysis.
¥Accepted surrogates = all the recommendations with surrogate acceptability classified as: yes (e1) = implicit yes “evidence 1”; yes (e2) = implicit yes “evidence 2”;
yes (used) = implicit yes “used before”; yes (ref) = implicit yes “reference”; yes (e) = explicit yes; N/S = no statement; N/A = not applicable.
§Not-accepted surrogates = all the recommendations with surrogate acceptability classified as: no (e2) = implicit no “evidence 2”; no (ref) = implicit no “reference”;
no (e) = explicit no “evidence 1”; no (e1 + e2) = explicit no “evidence 1” and implicit no “evidence 2”.
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for analgesics and arthritis drugs (such as pain scores,
ACR20, etc.) – therapeutic areas that rely exclusively on
clinical endpoints and scales. On the other hand, surro-
gate outcomes were used exclusively for HIV antire-
trovirals and diabetes drugs. In HIV, viral load was
accepted in every submission, and these drugs were also
associated with a 100% acceptance rate (0% DNL rate).
In diabetes, HbA1C was used universally. For type 1 dia-
betes, HbA1C was never questioned as an appropriate















Figure 1 Percentage of drug recommendations with surrogate outcom
surrogate outcomes. X axis: Therapeutic area.for two of three type 2 oral diabetes drugs. Surrogate
outcomes were also used frequently (89%) with drugs
for rare diseases, since the natural history of these dis-
eases is usually not well elucidated. Surrogates such as
blood pressure and lipid levels were common in cardio-
vascular disease (76% of submissions). Infectious disease
was split between acute infections which could employ
final outcomes (cure rates) for 64% of these submis-
sions, and chronic infections where the time horizon of
downstream outcomes required use of surrogates (36%
of submissions: hepatitis B and C).100% 100%
36% 38%
89%






















HIV (n=14) ID (n=5) Misc.
(n=20)
Rare (n=8)
Figure 2 Percentage of drug recommendations with surrogate acceptability by therapeutic area. Y axis: Percent of surrogate outcomes
with acceptability. X axis: therapeutic area. CV = cardiovascular; HIV = human immunodeficiency virus; ID = infectious disease; Misc. = miscellaneous.
Non-accepted surrogates for CV: 4/5 in pulmonary arterial hypertension; ID: 4/4 in hepatitis B; diabetes: 2/2 were oral antidiabetic agents. Rocchi et al.
Surrogate Outcomes at the CDR.
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Compared to accepted surrogates, non-accepted surrogates
were significantly more likely to be first-in-class (50% ver-
sus 15%, OR 5.7; p = 0.003) and for life-threatening diseases
(32% versus 8%, OR 5.8; p = 0.015). Non-accepted sur-
rogates were more frequently first for disease drugs (18%
versus 5%, OR 4.1; p = 0.106), and requested for priorityCDR HC FDA
Saxagliptin
(HbA1c) no (e2) N/S yes (e)
Sitagliptin
(HbA1c) no (e2) N/S yes (e)
Sitagliptin/Metformin

















(6MWD) no (e2) N/A no (e2)
Adefovir
(composite) no (e1) N/A yes (e)
Entecavir
(composite) N/S N/S yes (e2)
peg-IFN RB
(SVR) no (e1+e2) N/A N/S
Telbivudine
(composite) no (e2) no (e1) yes (e)
Tenofovir
(composite) no (e1) N/A N/A
Figure 3 Comparison of international agencies: concerns with surrogate
no “evidence 2”; no (ref) = implicit no “reference”; no (e) = explicit no “evidence
yes (e1) = implicit yes “evidence 1”; yes (e2) = implicit yes “evidence 2”; yes (used
explicit yes; Not identified: N/S = no statement; N/A = not applicable; Red shade
statement of surrogate acceptability; HbA1c = hemoglobin A1c; 6MWD= 6 min
virological response; CDR = Common Drug Review; HC =Health Canada; FDA =
NICE =National Institute for Health and Clinical Excellence; PBS = Pharmaceuticareview (32% versus 18%, OR = 2.2, p = 0.166) but these dif-
ferences were not significant.
Agency comparison
Figure 3 depicts the results of the comparison between
agencies, with acceptance of surrogates depicted using a
red-green colour scheme (red for non-accepted surrogates,EMA NICE PBS SMC
yes (e1) N/A N/S no (ref)
N/S N/A N/S no (e2)
yes (e1) N/A N/A N/S
yes (e) N/A no (ref) no (e2)
yes (used) N/A N/S no (e2)
yes (e) N/A N/S N/A
no (e1) N/A N/S N/A
N/A N/A N/S N/A
yes (e)
yes 
(used) no (e1) N/S
yes (guid) yes (e1) yes (e) N/S
yes (used) yes 
(used)
N/A N/S
yes (guid) yes (e1) yes (e) N/S
yes (guid) N/S N/S N/S
outcomes. Y axis: Drug submission. X axis: Agency. *No: no (e2) = implicit
1”; no (e1 + e2) = explicit no “evidence 1” and implicit no “evidence 2”; Yes:
) = implicit yes “used before”; yes (ref) = implicit yes “reference”; yes (e) =
s = negative statements of surrogate acceptability; Green shade = positive
ute walk distance; composite = histology, virology, serology; SVR = sustained
Food and Drug Administration; EMA= European Medicines Agency;
l Benefit Scheme; SMC= Scottish Medicines Consortium.
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were included in this analysis were chosen based on the
criteria that the CDR expressed concerns with the out-
comes used for almost all drugs in these therapeutic areas.
Predictably, therefore, there was a high level of lack of ac-
ceptability at the CDR (77% of recommendations).
Not all drugs were reviewed by all HTA agencies, de-
pending on their respective mandates. In particular,
while the CDR receives submissions for almost every
new chemical entity for outpatient use in Canada, NICE
does not – and in fact only reviewed five of the thirteen
drugs. NICE rendered four ‘implicit acceptance’ of the
surrogates used for hepatitis drugs, with the fifth as ‘no
statement’. PBAC and SMC generally avoided qualitative
statements about surrogates (for 64% of PBAC reviews
and 60% of SMC reviews). Of the submissions that in-
cluded qualitative statements about surrogates, these
were often negative (two of four for PBAC and four of
four for SMC).
Regulatory agencies often provided explicit statements
of acceptance of the surrogate outcome (83% of EMA re-
views and 64% of FDA reviews). Negative statements were
rare at regulatory agencies, with only one for each agency.
Health Canada had the least accessible reviewers’ reports
with which to inform the analysis.
Discussion
The CDR embraces an evidence-driven process that relies
on comparative effectiveness, cost-effectiveness and price,
while simultaneously weighting multiple factors. As with
similar central HTA agencies, clinical uncertainty is crit-
ical to the discussion. This research has shown that sur-
rogate acceptability was closely aligned with clinical
uncertainty – a predictable association, but important to
establish as a preface to more in-depth analysis. An un-
accepted surrogate, clinical uncertainty and a DNL recom-
mendation was a common triad – which seems entirely
reasonable and appropriate. Often, there was also a higher
price than comparators, raising the importance of an eco-
nomic model to determine incremental value.
This research has also shown that submissions based
on surrogates were more likely to receive a positive rec-
ommendation. A well-accepted surrogate, such as HIV
DNA viral load, can facilitate rapid and efficient clinical
trials, regulatory approval and comparative evaluation by
HTA agencies. Accepted surrogate outcomes were asso-
ciated with a low DNL rate of 25%. Surrogate acceptance
was more common when price was commensurate with
comparators: the bar for clinical certainty, and the ac-
ceptability of a surrogate, is partially set by the price of
the new intervention.
The Rocchi et al. analysis of CDR recommendations
found that there were statistically significant differences
in DNL rates between therapeutic areas [4]. Similarly,this analysis found a highly non-random distribution of
types of outcomes across therapeutic areas. The concern
is that any systematic lack of preference for surrogate
outcomes could lead to high barriers to access for the
therapeutic areas that rely on surrogate outcomes.
It was a challenge to identify reasons for surrogate ac-
ceptability. An obvious reason was a relative lack of epide-
miologic evidence to link surrogates with final outcomes,
or drugs to final outcomes – typically due to a long-term
horizon for such events (hepatitis B) or the challenge of
studying infrequent events or small populations (drugs for
rare diseases). In contrast, excellent epidemiological data
confirmed that antiviral drugs which reduce HIV DNA
viral loads to negligible levels will dramatically reduce HIV
mortality [19]. (Note that viral load is the same surrogate
outcome that is considered inadequate for hepatitis B).
Outside of epidemiology, however, there was consider-
able variation in the acceptability of the same surrogate
between different drug submissions. Unknown potential
long-term safety issues with new classes of drugs could
shift the perception of an otherwise-accepted surrogate,
eliciting a preference for final outcome studies to confirm
that the expected improvements in efficacy also improved
overall safety (such as new drug classes of antihyperten-
sives or oral diabetic agents). Evolutions in clinical practice
could change the acceptability of a surrogate, either with
the evaluation of more recent drugs, or on resubmission
of an earlier drug. Premium pricing was noted above as
another reason for variation in acceptability for the same
surrogate.
Oral diabetes drugs were an interesting example of
multiple surrogate-related issues. HbA1c is recognized
in international clinical practice guidelines as the rele-
vant treatment goal and primary outcome for clinical tri-
als [20,21]. HbA1c was never raised as a concern for
insulins at the CDR, whether they were used for Type 1
or Type 2 diabetes. However, HbA1c was rejected as a
surrogate for an oral Type 2 antidiabetic agent (sitaglip-
tin). At the time, conflicting epidemiologic studies were
published about the benefits of aggressive HbA1c reduc-
tion in Type 2 diabetics with long-standing cardiovascu-
lar disease. Beyond the epidemiologic confusion about
HbA1c, the submissions involved a new class of drugs,
with the attendant long-term safety concerns. The new
drugs entered the oral diabetes market with prices
higher than the existing, older and genericized products.
The decline in utilization of another oral drug class (the
glitazones) left a clinical vacuum that eventually in-
creased pressure for access to alternative agents.
For the selected drugs studied in the international com-
parison, other international HTA agencies less frequently
stated concerns about the use of surrogates. In most cases,
there was no comment on the surrogate at all from HTA
agencies (which is not necessarily an endorsement of the
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missions for which the CDR had voiced concerns, which
was a clear bias. However, these were therapeutic areas for
which outcomes were clearly a challenge: there was con-
siderable consternation across agencies regarding hepatitis
drugs because of the long horizon for downstream out-
comes, and with respect to pulmonary arterial hyperten-
sion drugs, because of uncertain value of improved
exercise tolerance and any putative relationship to overall
survival. Comments from other agencies focused more on
the complex and challenging nature of clinical research in
these therapeutic areas, rather than specific concerns
about the use of a specific surrogate. Possible explanations
for discrepancies between HTA agencies could include:
different mandates, different legislative environments, dif-
ferent expert panel composition, different normative expec-
tations around evidence, and/or different risk tolerances
around extrapolation of evidence.
Regulatory agencies had few concerns, and in fact
often had positive statements of acceptance about surro-
gate outcomes. Note however that the body of clinical
evidence developed by manufacturers at the time of
launch is intended specifically to meet the informational
needs of a regulatory agency (and not necessarily a reim-
bursement or HTA agency). Consequently, the use of
surrogate outcomes can be entirely appropriate for these
agencies, particularly to support intermediate treatment
objectives specified in a product monograph, such as
‘regulation of blood glucose’ or ‘improvement in exercise
capacity’.
The same drug file, presumably based on the same
pivotal clinical trials, could generate statements ranging
from an explicit acceptance to an explicit rejection (e.g.
adefovir, telbivudine). Statements regarding HbA1c for
sitagliptin ranged from ‘a very well accepted surrogate…
[which] predicts both microvascular and macrovascular
complications’ by the FDA to the CDR: ‘there is an ab-
sence of direct evidence on whether sitagliptin reduces
micro or macro vascular outcomes and the relationship
between HbA1c and vascular outcomes may differ for
new drug classes’. These opposing comments may be
due to the examination of a different evidence base [22],
but are more likely due to the interpretation of that evi-
dence base, and in fact may highlight the difference in
mandates, methodology and reporting between and
within regulatory and HTA agencies.
The aim of this analysis was to examine data at an ag-
gregate level and to identify patterns in surrogate accept-
ability. It was outside of the scope and the objectives of
this analysis to examine the merits of any individual
drug or any individual recommendation. Furthermore,
the analysis was restricted to the publicly available infor-
mation. While this information is not comprehensive of
the reimbursement evaluation and recommendation, it isnevertheless the only information available for external
parties to analyze and interpret. As such, it has an inher-
ent legitimacy in representing the reality known to the
multitude of external stakeholders, rather than the few
directly involved in the decision-making process.
A major challenge with this analysis was the subjectivity
of data abstraction. Definitions and rules of hierarchy for
surrogate acceptability were evolved for the analysis, as
each additional recommendation added complexity to the
task. This was further complicated by including recom-
mendations from multiple agencies, with different report-
ing structures and expectations. This was evidenced by
expanding the original binary categorization of accepted/
non-accepted surrogate for the CDR-specific analysis to
the eventual ten-level categorization of surrogate accept-
ability. Operationally, the categories expanded as subse-
quent recommendations presented fresh challenges; then,
each previous recommendation had to be re-reviewed in
the context of the evolving acceptability categorization.
This greater complexity allowed better characterization of
surrogate acceptability, although there were still challen-
ging instances when both positive and negative comments
were expressed in the same recommendation.
Surrogate outcomes have long posed problems to
regulatory and reimbursement agencies, as well as to cli-
nicians and clinical practice guideline working groups
[7,9,23,24]. This challenge has only increased over time,
as pressures to accelerate drug approval times has led to
increasing use of surrogate outcomes – to the point
where the surrogate itself may be posited as a meaning-
ful outcome (such as progression free survival in cancer)
[25,26]. Despite broad use and adoption of surrogate
outcomes, unpredictable risks remain in assuming causal
relationships between surrogates and clinical outcomes
[27]. HTA agencies show appropriate caution when con-
sidering surrogates. Inevitably, however, reimbursement
decisions must be made in the context of uncertainty, at
an early point in a product’s life cycle, often with incom-
plete epidemiologic data and always with a lack of long-
term data. The time lag in evidence development can be
addressed with a number of different strategies, to better
align the disparate informational needs of the HTA
agency and the regulatory authority. Where the evidence
is weak for a causal relationship between a surrogate
and downstream clinical events, strategies to reduce un-
certainty might include: early tripartite dialogue, cover-
age with evidence development, adaptive (progressive)
licensing, epidemiological research and/or simple post-
marketing randomized controlled trials [16].
Given the pivotal role of surrogate outcomes in drug
development, and the observed variability in surrogate
acceptability both within and between international
agencies, more clarity is needed on the nature and tim-
ing of evidence needed to validate surrogate outcomes.
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searchers, industry, regulatory agencies, reimbursement
agencies and other interested parties) to define and achieve
adequate surrogate validation.
Conclusions
While the majority of surrogate outcomes were accepted at
the CDR, those that were non-accepted were significantly
associated with clinical uncertainty and a DNL recommen-
dation. There was inconsistency of surrogate acceptability
across several international agencies. The findings of this
study emphasize a need for clinical, regulatory, reimburse-
ment and industry stakeholders to consider collaboratively
establishing guidelines and principles on the use, valid-
ation, and acceptability of surrogates.
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